Point-of-Care IVDs: Planning De Novo, CLIA Waiver and the Pre-Submission That Shapes Both

If you are building a novel point-of-care diagnostic, for example a saliva-based test that stratifies disease risk outside a central laboratory, you are almost certainly facing two regulatory decisions at once. First, your test probably has no legally marketed predicate, which points to the De Novo pathway. Second, if you want the test used in clinics, pharmacies or other non-laboratory settings, you need a CLIA waiver. A third decision shapes both: what you ask FDA in your pre-submission meeting, and when.

Teams that treat these as three separate workstreams tend to run the wrong studies in the wrong order. This guide explains how the pieces fit, and introduces the free Cahir MedTech Point-of-Care IVD De Novo and CLIA Waiver Planner.

Why most novel point-of-care tests land on De Novo

The 510(k) pathway requires a predicate: a legally marketed device with the same intended use and similar technological characteristics. Genuinely novel tests, new sample matrices, new biomarker combinations, new risk-scoring approaches, usually have none. Our guide to what happens when you do not have a predicate walks through the analysis, and how to choose between 510(k), De Novo and PMA compares the routes.

The De Novo pathway classifies novel low-to-moderate-risk devices into class I or II. A granted De Novo creates a new regulation, defines special controls, and turns your device into a potential predicate for everyone who follows. That last point is a genuine competitive asset: the special controls you help define become the bar your competitors must clear. Budget matters too; see what small businesses actually pay for De Novo in 2026.

What a CLIA waiver adds on top

FDA authorization to market a test is not the same as permission to run it outside a laboratory. Under the Clinical Laboratory Improvement Amendments, every site testing human samples needs a CLIA certificate, and the test's complexity categorization determines which certificate types can use it. FDA categorizes tests; CMS oversees the laboratories.

A waived test can be performed in settings holding a Certificate of Waiver, which is what makes true point-of-care distribution possible. To win a waiver through a CLIA Waiver by Application, you must show the test is simple and has an insignificant risk of an erroneous result, under the statutory criteria in 42 U.S.C. 263a(d)(3) and the expectations in FDA's CLIA waiver guidance. In practice that means:

• **Flex studies** that stress the test against foreseeable misuse: wrong sample volume, temperature extremes, dropped cartridges, interrupted runs.
• **Intended-user studies** showing untrained operators in real point-of-care settings get accurate results.
• **Labeling comprehension** showing lay users understand the instructions and the limitations.
• **A failure-mode risk analysis** demonstrating that erroneous results are detected or prevented by design.

FDA also offers a dual submission pathway that combines the marketing submission and waiver application study design, which can save a full study cycle when planned early. Payment is a separate question again; our coverage of the PAMA delay and lab test payment cuts explains the reimbursement context for diagnostics.

One evidence plan, three decisions

The rows share studies. An intended-user performance study designed only for the waiver may not satisfy De Novo clinical performance expectations, and a clinical study run only in central labs cannot support a point-of-care claim. Designing one study program that answers both is the single biggest cost lever a point-of-care IVD team controls.

The pre-submission that de-risks both

The Q-Submission program gives you written FDA feedback and a meeting before you file. For a point-of-care IVD, the highest-value questions are about comparators, study populations, settings and users, because those choices determine whether one dataset can serve both the De Novo and the waiver. Our guide to getting pre-submission feedback before you file covers mechanics and timing.

Three rules make the meeting productive. Ask three to four focused questions, each with your proposed approach, rather than open-ended ones. Include draft study synopses with endpoints and comparators, because FDA responds to specifics. And hold the meeting before the pivotal protocol is locked, while feedback can still change the design. Teams still in early development should first read our companion guide on when R&D becomes regulated design controls work, because studies run before that transition often cannot be used as evidence.

Worked example: a saliva-based point-of-care test

Consider a test that measures biomarkers in saliva to stratify risk of a chronic condition at the point of care. The evidence plan has to answer matrix questions (is the analyte stable in saliva across collection devices, transport and storage?), analytical questions (precision, interference from food, drink and oral conditions), clinical questions (performance against the accepted reference standard in the intended population), and waiver questions (can a nurse or pharmacist run it correctly?). If the result feeds an algorithm, the AI-specific evidence in our guide to AI/ML diagnostics on novel sample matrices applies as well.

Each of those studies is cheaper when designed once, with both the De Novo and the waiver in mind, and confirmed with FDA in a pre-submission before enrollment begins.

How to use the free planner

The Point-of-Care IVD De Novo and CLIA Waiver Planner is a branded Excel workbook with a twelve-item De Novo readiness baseline, a CLIA waiver evidence tracker covering simplicity, flex studies and intended-user performance, a pre-submission meeting preparation sheet, and overlays for five product categories. Download it free with a work email from the toolkits page and track the plan in your company workspace.

For help drafting pre-submission briefing documents and study synopses, explore Cahir MedTech Copilot. To compare diagnostic pathways across markets, use MedTech Compass. Keep qualified regulatory and clinical review in the process.

Point-of-care IVD planning: quick answers

Does a novel point-of-care test need a De Novo?

Usually, yes, when no legally marketed predicate exists with the same intended use and similar technology. The De Novo pathway classifies novel low-to-moderate-risk devices and creates special controls that later devices can use as a predicate.

Is FDA clearance enough to sell a test for point-of-care use?

No. The testing site needs an appropriate CLIA certificate, and the test's complexity categorization determines which sites can run it. A CLIA waiver allows use in settings holding a Certificate of Waiver, which is what enables broad point-of-care distribution.

What does FDA require for a CLIA waiver?

Evidence that the test is simple and has an insignificant risk of an erroneous result: flex studies, risk analysis of failure modes, performance with untrained users in intended settings, and labeling comprehension data.

Can one study support both the De Novo and the CLIA waiver?

Often, yes, if it is designed that way from the start and confirmed with FDA through a pre-submission. Studies designed for only one purpose frequently miss elements the other decision needs.

When should I request a pre-submission meeting?

Before the pivotal study protocol is locked. The meeting is most valuable while FDA feedback can still change comparators, endpoints, populations and settings.

Is the Cahir MedTech planner an FDA or CMS form?

No. It is a free, work-email-gated Excel planning aid. It does not replace FDA submissions, CLIA applications, or qualified regulatory and clinical review.

Sources

• FDA: De Novo classification request
• FDA: Clinical Laboratory Improvement Amendments (CLIA)
• FDA: CLIA Waiver by Application
• FDA: CLIA waiver applications guidance (February 2020)
• FDA: Dual 510(k) and CLIA waiver by application studies guidance
• FDA: Q-Submission program guidance
• CMS: Clinical Laboratory Improvement Amendments

Published November 4, 2026. Sources checked for this edition; confirm current FDA and CMS requirements for your test. This article and planner are educational planning tools, not legal, regulatory or clinical advice.